Trial Profile

A Non-interventional Study of Carfilzomib (Kyprolis) in Combination With Lenalidomide (Revlimid) and Dexamethasone or Carfilzomib in Combination With Dexamethasone Alone or Carfilzomib in Combination With Daratumumab (Darzalex) and Dexamethasone in Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2025 Results evaluating patients adherence and persistence to carfilzomib therapy in combination with lenalidomide and dexamethasone published in the Leukemia and Lymphoma.
07 Jul 2023 Status changed from recruiting to active, no longer recruiting.
02 Jun 2022 Planned End Date changed from 30 Sep 2024 to 30 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com